OR WAIT null SECS
February 17, 2020
An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.
January 06, 2020
The new GMP conditioning product offering is designed to support clinical phase and commercialization stages of cell and gene therapy production.
September 01, 2019
Innovation in manufacturing technologies must occur to ensure the availability of gene and cell therapies.
February 01, 2019
New platform technologies, advanced modeling tools, and addressing patient needs are important developments.
November 26, 2018
ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.
August 16, 2018
FDA grants support US research in continuous manufacturing monitoring and control techniques for bio/pharmaceutical manufacturing at Rutgers, MIT, and Georgia Tech.
August 08, 2018
Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.
August 01, 2018
Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.
The changing regulatory and manufacturing environment is ushering in a new approach to drug development.
July 19, 2018
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.